[go: up one dir, main page]

MX2021008144A - Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso. - Google Patents

Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.

Info

Publication number
MX2021008144A
MX2021008144A MX2021008144A MX2021008144A MX2021008144A MX 2021008144 A MX2021008144 A MX 2021008144A MX 2021008144 A MX2021008144 A MX 2021008144A MX 2021008144 A MX2021008144 A MX 2021008144A MX 2021008144 A MX2021008144 A MX 2021008144A
Authority
MX
Mexico
Prior art keywords
compositions
life
methods
canines
increase
Prior art date
Application number
MX2021008144A
Other languages
English (en)
Inventor
William Brondyk
Brett Chevalier
Juergen Horn
Madhusudan Natarajan
Original Assignee
Invetx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invetx Inc filed Critical Invetx Inc
Publication of MX2021008144A publication Critical patent/MX2021008144A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan composiciones para aumentar la vida media de un polipéptido o polipéptidos en un canino y métodos para su uso. Las composiciones implican regiones Fc de IgG canina variantes.
MX2021008144A 2019-01-03 2020-01-02 Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso. MX2021008144A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962788035P 2019-01-03 2019-01-03
PCT/US2020/012081 WO2020142625A2 (en) 2019-01-03 2020-01-02 Compositions for increasing half-life of a therapeutic agent in canines and methods of use

Publications (1)

Publication Number Publication Date
MX2021008144A true MX2021008144A (es) 2021-10-13

Family

ID=69740520

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008144A MX2021008144A (es) 2019-01-03 2020-01-02 Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.

Country Status (9)

Country Link
US (7) US11542333B2 (es)
EP (1) EP3906259A2 (es)
CN (2) CN113544153B (es)
AU (1) AU2020205073A1 (es)
BR (1) BR112021012513A2 (es)
MA (1) MA54657A (es)
MX (1) MX2021008144A (es)
SG (1) SG11202106478UA (es)
WO (1) WO2020142625A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
CN119390821A (zh) 2017-08-15 2025-02-07 伊兰科美国公司 兽药用IgG Fc变体
US12351622B2 (en) * 2018-12-05 2025-07-08 Bica Therapeutics Inc. Modified product of Fc domain of antibody
CN113544153B (zh) 2019-01-03 2024-12-10 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
CN115135669A (zh) 2020-02-19 2022-09-30 艾迪沃有限责任公司 修饰的Fc区
CN115996949A (zh) * 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体
GB202005879D0 (en) * 2020-04-22 2020-06-03 Petmedix Ltd Heterodimeric proteins
JP2023524643A (ja) * 2020-04-22 2023-06-13 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための長時間作用性抗ｉｌ３１抗体
US11434276B2 (en) 2020-05-11 2022-09-06 Invetx, Inc. Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use
EP4166574A4 (en) * 2020-06-10 2025-01-15 Bica Therapeutics Inc. FUSION PROTEIN WITH ERYTHROPOIETIN POLYPEPTIDE
WO2022010652A1 (en) 2020-07-10 2022-01-13 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
CA3194936A1 (en) * 2020-09-28 2022-03-31 Zoetis Services Llc Canine antibody variants
CN117043190A (zh) 2020-12-07 2023-11-10 因外泰克斯公司 延长治疗剂在家畜动物中的半衰期的组合物和使用方法
US20240059777A1 (en) * 2021-01-28 2024-02-22 Zoetis Services Llc Mutations in canine antibody constant regions
JP2024530036A (ja) * 2021-08-06 2024-08-14 ペットメディックス・リミテッド 抗体Ｆｃバリアント
AU2022329459A1 (en) * 2021-08-20 2024-02-29 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
US11608371B1 (en) * 2021-10-21 2023-03-21 Petmedix Ltd Therapeutic molecules
KR20240099321A (ko) 2021-10-21 2024-06-28 펫메딕스 리미티드 P75ntr의 세포외 도메인을 포함하는 단백질
EP4448571A1 (en) * 2021-12-16 2024-10-23 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha ii
JP2026500341A (ja) * 2022-12-16 2026-01-06 ヴェットマブ バイオサイエンシーズ， インコーポレイテッド 抗ＩＬ２３及び抗ＴＮＦα抗体：組成物ならびに獣医学的使用
EP4642795A2 (en) 2022-12-27 2025-11-05 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
CN121002059A (zh) 2023-01-20 2025-11-21 因外泰克斯公司 用于伴侣动物的双特异性结合剂
WO2024153949A1 (en) 2023-01-20 2024-07-25 Petmedix Ltd Therapeutic antibodies
CN120712277A (zh) 2023-02-09 2025-09-26 佩特迈迪有限公司 包含p75神经营养因子受体(p75ntr)胞外结构域变体的治疗分子
AU2024222373A1 (en) * 2023-02-13 2025-08-07 Intervet International B.V. Canine antibodies to canine il-13
EP4665756A1 (en) * 2023-02-13 2025-12-24 Intervet International B.V. Canine antibodies to canine il-4

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
CA2105984C (en) 1991-03-11 2002-11-26 Milton J. Cormier Cloning and expression of renilla luciferase
US6146826A (en) 1993-09-10 2000-11-14 The Trustees Of Columbia University In The City Of New York Green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
JP3795533B2 (ja) 1996-12-12 2006-07-12 プロルーム・リミテツド 感染性物質を検出及び同定するための方法及び装置
ATE388224T1 (de) 1998-03-27 2008-03-15 Prolume Ltd Luciferase, gfp fluoreszenzproteine, kodierende nukleinsaüre und ihre verwendung in der diagnose
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
CA2577133A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2010110838A2 (en) * 2009-03-25 2010-09-30 Vet Therapeutics Inc. Antibody constant domain regions and uses thereof
US20120093814A1 (en) * 2009-03-30 2012-04-19 Boehringer Ingelheim International Gmbh Fusion Proteins Comprising Canine FC Portions
WO2010117448A2 (en) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
CA2871807C (en) * 2012-04-27 2022-10-04 Bioatla, Llc Modified antibody regions and uses thereof
EA201791754A1 (ru) * 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
CA2980992C (en) * 2015-04-14 2024-01-23 Akihisa Kaneko Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
CN110267674A (zh) * 2016-07-08 2019-09-20 奥美药业有限公司 包含瘦素的融合蛋白及其生产和使用方法
CA3040823A1 (en) * 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
CN119390821A (zh) 2017-08-15 2025-02-07 伊兰科美国公司 兽药用IgG Fc变体
WO2019177690A1 (en) 2018-03-12 2019-09-19 Zoetis Services Llc Anti-ngf antibodies and methods thereof
MX2021002971A (es) * 2018-09-14 2021-05-12 Kindred Biosciences Inc Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
MX2021004313A (es) 2018-10-18 2021-05-27 Kindred Biosciences Inc Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
US12351622B2 (en) 2018-12-05 2025-07-08 Bica Therapeutics Inc. Modified product of Fc domain of antibody
CA3123623A1 (en) 2018-12-27 2020-07-02 Kindred Biosciences, Inc. Igg fc variants for veterinary use
CN113544153B (zh) 2019-01-03 2024-12-10 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
CN115135669A (zh) 2020-02-19 2022-09-30 艾迪沃有限责任公司 修饰的Fc区
CA3176434A1 (en) 2020-04-17 2021-10-21 Zoetis Services Llc Feline antibody variants
CN115996949A (zh) 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体
US11434276B2 (en) 2020-05-11 2022-09-06 Invetx, Inc. Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use
WO2022010652A1 (en) 2020-07-10 2022-01-13 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use

Also Published As

Publication number Publication date
US20240166748A1 (en) 2024-05-23
WO2020142625A2 (en) 2020-07-09
US20230279118A1 (en) 2023-09-07
US11548949B2 (en) 2023-01-10
CN113544153A (zh) 2021-10-22
WO2020142625A3 (en) 2020-10-08
EP3906259A2 (en) 2021-11-10
US11542333B2 (en) 2023-01-03
SG11202106478UA (en) 2021-07-29
US20240239897A1 (en) 2024-07-18
US20200362035A1 (en) 2020-11-19
US20240239896A1 (en) 2024-07-18
CN120005022A (zh) 2025-05-16
WO2020142625A4 (en) 2020-12-10
WO2020142625A9 (en) 2021-06-24
MA54657A (fr) 2021-11-10
US20240166749A1 (en) 2024-05-23
US20200216536A1 (en) 2020-07-09
CN113544153B (zh) 2024-12-10
BR112021012513A2 (pt) 2021-09-14
AU2020205073A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
MX2021008144A (es) Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.
BR112022022922A2 (pt) Composições para aumentar a meia-vida de um agente terapêutico em caninos e métodos de uso
MX2017001062A (es) Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso.
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
IL282223A (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
MX2022006758A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
CL2019001136A1 (es) Inmunoglobulinas y usos de estas.
WO2019204592A8 (en) Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
BR112022027028A2 (pt) Composições para aumentar a meia-vida de um agente terapêutico em felinos e métodos de uso
MX386014B (es) Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
JOP20200343A1 (ar) بروتين ربط مولد ضد مضاد لـ steap1
MX2018005063A (es) Polipéptidos condicionalmente activos.
EP3352858A4 (en) ANTIBODIES BINDING TO HUMAN PROGRAMMED DEATH LIGANDS 2 (PD-L2) AND USE THEREOF
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
CO2021010697A2 (es) Formulación de anticuerpos terapéuticos
JOP20210326A1 (ar) أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
PE20170287A1 (es) Anticuerpos anti-proteina similar a angiopoyetina 4 y metodos de uso
JOP20200329A1 (ar) بروتينات وشظايا سائدة مناعيا في التصلب المتعدد
MX2024012582A (es) Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso
MX2018013177A (es) Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas.